July 14, 2022 02:17 PM EDT

#BIO22: De­cen­tral­ized tri­als

Zachary Brennan

Senior Editor

Zachary Bren­nan:

Hel­lo. Good morn­ing. I’m Zachary Bren­nan, se­nior ed­i­tor at End­points News. And thank you for join­ing us vir­tu­al­ly at BIO for our pan­el …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times